Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | FLT4 | P35916 | 2/20 | 0.47 |
| ▸ | FES | P07332 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | MARK3 | P27448 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | CASR | P41180 | 4/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5557501 | 0.81 | FLT4 (0.55) | EPHX2CYP2C9CYP2C19FLT4FES | |
| SCHEMBL5557494 | 0.80 | FES (0.76) | EPHX2CYP2C9CYP2C19FLT4FES | |
| SCHEMBL5557436 | 0.79 | CYP3A4 (0.48) | FLT4FESRETMARK3TYK2 | |
| SCHEMBL5557341 | 0.77 | KMT2A (0.60) | — | |
| SCHEMBL14559615 | 0.73 | CASR (0.58) | EPHX2CASRMTNR1AMTNR1B | |
| SCHEMBL12913969 | 0.73 | KDM1A (0.73) | EPHX2CASRMTNR1AMTNR1BHDAC6 | |
| SCHEMBL14333524 | 0.72 | OXER1 (0.45) | FLT4FESRETMARK3TYK2 | |
| SCHEMBL12913677 | 0.71 | KDM1A (0.70) | EPHX2CASRMTNR1AMTNR1BHDAC6 | |
| SCHEMBL16243504 | 0.71 | KDM4E (0.44) | LMNAHDAC6 | |
| SCHEMBL4137357 | 0.70 | NAAA (0.58) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1154998-B1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-09-26 | — | — | EP | claimed |
| US-6506572-B2 | Inhibitor of niacinamide phosphoribosyl transferase (NAPRT) | KLINGE PHARMA GMBH (DE) | 2003-01-14 | — | — | US | claimed |
| JP-2002537380-A | — | — | 2002-11-05 | — | — | JP | claimed |
| US-20020160968-A1 | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy | KLINGE PHARMA GMBH | 2002-10-31 | — | — | US | claimed |
| EP-1154998-A1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | Klinge Pharma GmbH (DE) | 2001-11-21 | — | — | EP | claimed |
| WO-2000050399-A1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | KLINGE PHARMA GMBH (DE) | 2000-08-31 | — | — | WO | claimed |
| EP-1031564-A1 | Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy | Klinge Pharma GmbH (DE) | 2000-08-30 | — | — | EP | claimed |
| EP-1154998-B1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-09-26 | — | — | EP | disclosed |
| EP-1816124-A2 | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy | Astellas Deutschland GmbH (DE) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160968-A1 | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy | NAMPT, NAPRT, NNT | EPHX2 2339/4885CYP2C9 1567/4885CYP2C19 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.